The role of calcium supplementation in healthy musculoskeletal ageing : An expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF).
Study Goal
The researchers aimed to evaluate the efficacy and safety of calcium supplementation, with or without vitamin D, for promoting healthy musculoskeletal aging and reducing fracture risk.
Results Summary
The study found that calcium and vitamin D supplementation modestly reduces fracture risk, though population-level intervention was ineffective. Calcium alone was not supported for fracture reduction, and side effects included renal stones and gastrointestinal symptoms. Vitamin D, rather than calcium, may reduce falls risk, and cardiovascular risks from calcium supplementation were not convincingly supported.
Population
Patients at high risk of calcium and vitamin D insufficiency, and those receiving osteoporosis treatment.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
calcium supplementation, with or without vitamin D supplementation | decrease | fracture risk | patients at high risk of calcium and vitamin D insufficiency, and in those who are receiving treatment for osteoporosis | modest | leads to a modest reduction | #1 |
calcium supplementation, with or without vitamin D supplementation | no change | fracture risk | general population | no significant change | population-level intervention has not been shown to be an effective public health strategy | #2 |
calcium supplementation alone | no change | fracture reduction | - | - | is not supported by the literature | #3 |
calcium supplementation | increase | renal stones and gastrointestinal symptoms | - | - | side effects include | #4 |
vitamin D supplementation | decrease | falls risk | - | - | may reduce | #5 |
calcium supplementation | no change | cardiovascular risk | - | - | assertions of increased cardiovascular risk are not convincingly supported | #6 |
The place of calcium supplementation, with or without concomitant vitamin D supplementation, has been much debated in terms of both efficacy and safety. There have been numerous trials and meta-analyses of supplementation for fracture reduction, and associations with risk of myocardial infarction have been suggested in recent years. In this report, the product of an expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF), we review the evidence for the value of calcium supplementation, with or without vitamin D supplementation, for healthy musculoskeletal ageing. We conclude that (1) calcium and vitamin D supplementation leads to a modest reduction in fracture risk, although population-level intervention has not been shown to be an effective public health strategy; (2) supplementation with calcium alone for fracture reduction is not supported by the literature; (3) side effects of calcium supplementation include renal stones and gastrointestinal symptoms; (4) vitamin D supplementation, rather than calcium supplementation, may reduce falls risk; and (5) assertions of increased cardiovascular risk consequent to calcium supplementation are not convincingly supported by current evidence. In conclusion, we recommend, on the basis of the current evidence, that calcium supplementation, with concomitant vitamin D supplementation, is supported for patients at high risk of calcium and vitamin D insufficiency, and in those who are receiving treatment for osteoporosis.